Share This Author
Mortality results from a randomized prostate-cancer screening trial.
After 7 to 10 years of follow-up, the rate of death from prostate cancer was very low and did not differ significantly between the two study groups.
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
- J. Mcconnell, C. Roehrborn, Joseph A. Smith
- MedicineThe New England journal of medicine
- 18 December 2003
Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone.
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.
The combination of measurement of the serum PSA concentration and rectal examination, with ultrasonography performed in patients with abnormal findings, provides a better method of detecting prostate cancer thanrectal examination alone.
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
Observations indicate the presence of at least two independent loci within 8q24 that contribute to prostate cancer in men of European ancestry, and it is estimated that the population attributable risk of the new locus, marked by rs6983267, is higher than the locus marked byrs1447295.
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
There was no evidence of a mortality benefit for organized annual screening in the PLCO trial compared with opportunistic screening, which forms part of usual care, and there was no apparent interaction with age, baseline comorbidity, or pretrial PSA testing.
Effect of dutasteride on the risk of prostate cancer.
Over the course of the 4-year study period, dutasteride reduced the risk of incident prostate cancer detected on biopsy and improved the outcomes related to benign prostatic hyperplasia.
Multiple loci identified in a genome-wide association study of prostate cancer
The findings point to multiple loci with moderate effects associated with susceptibility to prostate cancer that, taken together, in the future may predict high risk in select individuals.
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
Among women in the general US population, simultaneous screening with CA-125 and transvaginal ultrasound compared with usual care did not reduce ovarian cancer mortality.
Radical prostatectomy versus observation for localized prostate cancer.
Among men with localized prostate cancer detected during the early era of PSA testing, radical prostatectomy did not significantly reduce all-cause or prostate-cancer mortality, as compared with observation, through at least 12 years of follow-up.